Market Place
Sourcing Support
All News #Library
Biotech
AviadoBio Advances AVB-101 & Starts Ph1/2 ASPIRE-FTD Cohort 4
31 Mar 2026 //
BUSINESSWIRE
AviadoBio Explores Eye Gene Therapy In $413M Ugenex Deal
10 Oct 2025 //
BIOSPACE
AviadoBio Announces ASPIRE-FTD Trial at UK Hospitals
15 May 2025 //
BUSINESSWIRE
AviadoBio Completes Phase 1/2 ASPIRE-FTD Trial for FTD-GRN
01 May 2025 //
BUSINESSWIRE
Astellas pays $50M for option on AviadoBio dementia gene therapy
08 Oct 2024 //
FIERCE BIOTECH
AviadoBio Doses First AVB-101 Frontotemporal Dementia Patient
15 Apr 2024 //
BUSINESSWIRE
AviadoBio Announces FDA IND Clearance and Fast Track Designation for AVB-101
06 Nov 2023 //
BUSINESSWIRE
AviadoBio Announces Presentation of Safety and Biodistribution Data of AVB-101
24 Oct 2023 //
BUSINESSWIRE
AviadoBio Announces Initiation of Phase 1/2 Evaluating AVB-101
10 Oct 2023 //
BUSINESSWIRE
AviadoBio Signs Exclusive License Agreement with Neurgain Technologies
23 Feb 2023 //
BUSINESSWIRE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.